Table 3. Expression levels of validated targets of miR-125a in hepatocellular carcinoma.

		Fold regulation (HCC/NC)
Etiology	Patient	MMP11	SIRT7	c-Raf	Zbtb7a
	1	n.d.	0.40	0.50	0.60
HBV	26	0.92	0.65	1.02	0.67
	30	5.07	1.85	0.95	1.41
	5	1.49	1.38	1.18	1,83
	32	1.61	2.51	1.53	0.05
	35	0.46	1.51	2.46	1.77
	36	4.61	4.20	2.47	2,29
HCV	39	n.d.	2.92	1.06	0.71
	43	3.44	2.42	1.99	0.54
	54	0.78	4.24	0.73	1.42
	56	9.97	1.95	5.35	0.36
	65	2.10	2.00	2.30	1.70
	23	2.50	n.d.	0.99	1.17
NASH	49	3.37	n.d.	1.53	0.70
	mean	3.03*	2.17*	1,72*	1.09

Expression levels were evaluated by RT-qPCR in a subset of patients with a downregulation of miR-125a of at least 2-fold. Data are reported as fold regulation for comparison of hepatocellular carcinoma (HCC) tissue with matched adjacent non-tumor liver tissue (NC). N.d., not determined because of the limited amount of tissue. * p < 0.05 at Wilcoxon test.